# A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

> **NCT04728711** · PHASE2 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Atopic Asthma

## Interventions

- **DRUG:** ADX-629
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04728711
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-09
- **Primary completion:** 2022-01-18
- **Final completion:** 2022-01-18
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728711, "A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04728711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*